For reprint rights or to purchase a copy of your Daily Journal photo, email jeremy@reprintpros.com for prices or call 949-702-5390.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Labor/Employment,
Consumer Law

Mar. 3, 2025

Direct-to-consumer prescription drug programs: Plan sponsors beware!

In 2024, Eli Lilly launched LillyDirect, a direct-to-consumer platform providing affordable access to various drugs, bypassing pharmacy benefit managers (PBMs) and raising concerns for employers about potential contract violations and the design of legal reimbursement programs.

Mary E. Powell

Director, Trucker Huss, APC

Email: MPowell@truckerhuss.com

Shutterstock

In 2024, Eli Lilly and Company announced LillyDirect, which is an online platform that offers individuals direct access to certain drugs, including Zepbound, a GLP-1 drug that is used to treat obesity. Eli Lilly partnered with telehealth companies that connect individuals with healthcare professionals who can prescribe Zepbound for the treatment of obesity. The prescription for $95

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up



By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.